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Abstract: Estrogens play well-recognized roles in reproduction across vertebrates, but also 
intervene in a wide range of other physiological processes, including mineral homeostasis. 
Classical actions are triggered when estrogens bind and activate intracellular estrogen 
receptors (ERs), regulating the transcription of responsive genes, but rapid non-genomic 
actions initiated by binding to plasma membrane receptors were recently described. A wide 
range of structurally diverse compounds from natural and anthropogenic sources have been 
shown to interact with and disrupt the normal functions of the estrogen system, and fish  
are particularly vulnerable to endocrine disruption, as these compounds are frequently 
discharged or run-off into waterways. The effect of estrogen disruptors in fish has mainly 
been assessed in relation to reproductive endpoints, and relatively little attention has been 
given to other disruptive actions. This review will overview the actions of estrogens in fish, 
including ER isoforms, their expression, structure and mechanisms of action. The estrogen 
functions will be considered in relation to mineral homeostasis and actions on mineralized 
tissues. The impact of estrogenic endocrine disrupting compounds on fish mineralized 
tissues will be reviewed, and the potential adverse outcomes of exposure to such 
compounds will be discussed. Current lacunae in knowledge are highlighted along with 
future research priorities. 
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1. Introduction 
Estrogens are ubiquitous, small steroid compounds that function as hormones mainly in vertebrates. 
The estrogen system in vertebrates is remarkably well conserved and includes steroidogenic enzymes 
involved in estrogen synthesis; the estrogens estrone, estriol and 17β-estradiol (E2, the most abundant 
and potent natural estrogen) (see Figure 1A), and estrogen receptors [1]. Estrogens are key regulators 
of physiological changes associated with reproduction in both sexes and also regulate many other 
important physiological processes, including immune function and mineral homeostasis [2–4]. 
Figure 1. Examples of the chemical structure of typical estrogenic compounds, including: 
(A) natural animal estrogens; (B) natural plant estrogenic compounds (phytoestrogens); 
and synthetic estrogenic compounds with pharmaceutical (C) or other applications (D). 
The compounds were selected to show the diversity of chemical structures reported to 
possess estrogenic effects, and compounds with reported effects in fish mineralized tissues 
were preferentially selected (see Section 7). 
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A wide range of compounds have now been identified that affect the function of the estrogen 
system and are classified as endocrine disrupting compounds (EDCs), which are ―exogenous 
substances or mixtures that alter the function(s) of the endocrine system and cause adverse health 
effects in an intact organism or its progeny‖ [5]. EDCs may act at several different levels, and the best 
studied actions are those in which compounds bind to estrogen receptors (ERs) and mimic or block 
normal estrogenic actions; however, other, less studied disruptive actions include alterations in 
receptor or hormone availability (affecting their synthesis, transport, metabolism and excretion), and 
other more recently identified mechanisms of action include disruption caused by binding to  
other receptors [6–8]. 
Estrogenic EDCs are structurally diverse compounds from multiple sources (see Figure 1 for 
examples) that have estrogenic and/or anti-estrogenic activities, although they may also affect  
other endocrine systems. Sources of estrogenic EDCs include natural estrogens produced by plants 
(phytoestrogens), fungi (mycoestrogens) and cyanobacteria, synthetic therapeutic drugs (e.g., raloxifene) 
and numerous synthetic compounds mainly used in industry and agriculture (e.g., polychlorinated 
biphenyls (PCBs), organochlorine pesticides, phthalate plasticizers or dioxins) [9,10]. 
Many EDCs are of anthropogenic origin and have been accumulating in the aquatic environment for 
decades, and their lipophilic and persistent nature means that they bioaccumulate and/or biomagnify  
in marine organisms [6,7]. Aquatic vertebrates, such as fish, are particularly affected by aquatic 
anthropogenic contaminants; exposure can be lifelong and through multiple routes, including the  
skin and gills or through feeding on contaminated sediments or organisms and bioaccumulation is 
frequent [11,12]. Aquatic contaminants can compromise reproduction, development, immune response 
and other physiological processes, which can ultimately affect the survival of fish [10,13,14]. In 
addition to the direct impact of aquatic contaminants on fish populations, the ecological importance of 
fish means that they also indirectly affect the environment and, when eaten by humans and wildlife, 
pose a health risk and negatively impact the economics of fisheries and aquaculture. 
The estrogenicity of EDCs have mostly been evaluated in relation to their binding and/or activation 
of intracellular ERs, which regulate many of estrogens’ actions in target cells [7,15]. The adverse 
outcomes of exposure to estrogenic EDCs have mainly been evaluated in relation to reproductive 
functions or tissues (e.g., induction of hepatic vitellogenin production, reduced gonadal growth, male 
gonad feminization, altered sex ratios) [5,10,15]. In contrast, the impact of EDCs on non-reproductive 
tissues is largely unexplored [7,16]. From fish to mammals, mineral homeostasis is regulated by 
estrogens, and mineralized tissues are estrogen targets [1], which makes them also a target for 
endocrine disruption.  
The present review compares the effects and diverse mechanisms of action of estrogens on fish 
mineralized tissues and the better studied mammalian bone. Evidence for estrogen responsiveness and 
endocrine disruption will be reviewed for fish mineralized tissues. The possible mechanisms of action 
and the impact of exposure to estrogenic EDCs on fish health and survival is discussed, in relation to 
the physiological importance of the skeletal system. 
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2. Mineralized Tissues and Mineral Homeostasis 
The skeleton has a well-recognized role in support, protection, locomotion and mineral homeostasis 
across vertebrates. Bone is a dynamic tissue maintained by continuous cycles of formation and 
resorption, mediated, respectively, by osteoblasts (OSB) and osteoclasts (OSC). Mammalian bone  
also contains cells embedded in the matrix, the osteocytes, that are crucial for the detection and  
response to mechanical loading, regulating bone remodeling and repair. Recently, mammalian bone  
has also been proposed to function as an endocrine organ that can influence reproduction and  
energy metabolism [17]. 
The fish skeleton consists of an articulated endoskeleton, like in mammals, but they also contain an 
exoskeleton formed by mineralized appendages, the fish scales. All fish mineralized tissues contain 
OSC and OSB that are thought to have the same role as in mammals. Fish bone is classified as 
acellular, because it lacks osteocytes [18], although salmonids and cyprinids are an exception, as they 
possess matrix dwelling osteocytes in some elements of the skeleton and, therefore, are considered to 
have cellular bone [19]. Due to the aquatic environment inhabited by fish, the skeleton is less exposed 
to mechanical loading; nonetheless, skeletal turnover and homeostasis are just as important as in 
mammals. Skeletal anomalies are a major concern in fish farms, as they can compromise fish survival 
and their economic value. 
Mineral homeostasis requirements and regulation differ between mammals and fish and between 
marine and freshwater fish. In terrestrial vertebrates, the bone serves as a reservoir of minerals, as the 
only available source is the diet, and so, if there is an increased need for calcium (Ca), phosphorus (P) 
or other minerals, bone can be mobilized [20]. In marine species of fish, an abundant source of Ca is 
present in the environment, and food is only essential to meet the demand for P. In contrast, in 
freshwater fish species, Ca ions are in poor supply in the surrounding environment, and the diet 
contributes to meet Ca and P requirements, as occurs in mammals. If Ca becomes limiting, it can 
compromise reproduction, growth and development, leading to the mobilization of both Ca/P from 
mineralized tissues. In fish, the scales appear to play an important role in Ca/P homeostasis and also 
function as a physical barrier and improve hydrodynamics [21]. However, an important aspect to bear 
in mind when considering fish is the vast number of species that exist (over 30,000) and their diversity 
of habitats and adaptations. This means that caution is required when making generalizations between 
fish species and even more so in relation to the results obtained in other vertebrates, such as mammals. 
More studies of skeletal homeostasis and endocrine disruption are required in a greater diversity of 
fish, and it remains to be established if the recent novel role of bone in energy homeostasis in 
mammals also occurs in fish. 
3. Estrogen Actions in Mineralized Tissues 
Estrogens regulate mineralized tissues physiology and mineral homeostasis across vertebrates [1], 
together with other hormones. In mammals, E2 protects the skeleton by favoring differentiation and 
increasing the life span of OSB, by inducing bone mineralization and by decreasing the formation, 
activity and life span of OSC. Thus, in mammals, estrogens contribute to the development and 
maintenance of bone mass, in both males and females [22–26]. 
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In fish, E2 induces an increase in plasma Ca levels and a decrease in scale Ca content in periods of 
increased demand, such as vitellogenesis in females [27–30]. This hypercalcemic effect appears to be 
mediated by several mechanisms, including an increase in Ca influx from the environment [2,31] and 
stimulation of Ca mobilization from mineralized tissues, especially the scales [32–34]. Indeed, in the 
scales of several marine and freshwater fish species, E2 increases the activity of tartrate-resistant acid 
phosphatase (TRAP), a marker of osteoclasts and scale resorption [33–38]. The results of such studies 
suggest that E2-induced Ca mobilization is especially increased in scales [39], which is in line with the 
protective role of E2 on mammalian bone. The effects of E2 on the fish endoskeleton remains to be 
fully characterized. 
In goldfish (Carassius auratus, a freshwater teleost) and wrasse (Pseudolabrus sieboldi, a marine 
teleost), E2 also increased osteoblast activity (measured by the activity of the OSB marker, alkaline 
phosphatase, ALP) [37,40], suggesting that estrogens could affect both mineralization and mobilization 
in fish scales, two processes that are often coupled in mammalian bone [22]. Furthermore, exposure of 
early-life-stage mosquito fish to E2 causes a change in hemal spine morphology indicative of delayed 
development [41], while in E2 treated adult sea bream (Sparus auratus), the proteome of regenerating 
skin and scales indicates that the process is accelerated [42]. However, further studies are required to 
establish in more detail and in a greater number of species the effects of E2 on fish bone/scale Ca 
content and turnover and if this differs across the reproductive cycle or in relation to environmental or 
internal cues. 
4. General Mechanisms of Estrogenic Action 
The actions of estrogens are mostly mediated by specific intracellular receptors, the ERs, which 
may be located in the cytoplasm, the nucleus or in other organelles [7,43,44]. While most vertebrates 
have duplicate ER genes (α and β), the teleost-specific whole genome duplication means that most 
have at least three ER isoforms, one ERα and two ERβs (reviewed by [45]). The ERs in teleost fish 
have been detected in the nucleus and cytoplasm [46–48]. 
In the classical model of estrogen actions (Figure 2A), ERs regulate gene expression in the nucleus 
of target cells by binding to estrogen-response elements (ERE) in the promoters of target genes [49,50]. 
Estrogens (as well as EDCs) can also act via alternative pathways (see Figure 2B–D for details), and 
studies in mammals reveal the indirect regulation of gene expression by interaction with other 
transcription factors (TFs) or by binding to membrane receptors, which may result in changes in gene 
expression or in rapid non-genomic effects, such as the activation of specific enzymes [7,50,51]. The 
nature of the receptors mediating membrane-initiated actions of estrogens remains controversial, but 
probably includes both classical ERs and their variants, as well as novel membrane receptors, such as 
the G protein-coupled estrogen receptor 1 (GPER, formerly known as GPR30), recently characterized 
in mammals and fish [52–54]. 
In fish, different mechanisms of E2 action have also been identified and include: (1) the direct 
genomic regulation of hepatic vitellogenin mRNA, a classical EDC biomarker, by intracellular ERs [55]; 
(2) disruption of ERα pathways by environmental contaminants through interaction with other transcription 
factors [56]; (3) indirect regulation of the luteinizing hormone β gene through ERα interaction with 
other TFs [57]; and (4) rapid GPER-mediated effects characterized in fish gonads [45,53]. 
Mar. Drugs 2014, 12 4479 
 
 
Figure 2. Simplified scheme presenting the possible mechanisms involved in the cellular 
actions of natural estrogens (e.g., 17β-estradiol, E2) and estrogenic endocrine disrupting 
compounds (EDCs). In the classical mode of action (A), an estrogenic ligand binds and 
activates intracellular estrogen receptors (in fish, ERα, ERβa or ERβb), which dimerize in 
the nucleus, bind to estrogen-response elements in the promoters of target genes and 
regulate their transcription, through the recruitment of a range of possible cell-specific  
co-regulators. Alternative mechanisms of action include: (B) indirect regulation of gene 
expression by interaction of ligand-bound ERs with other transcription factors (TF); (C,D) 
estrogen actions initiated by binding to membrane receptors (ERs or G-protein coupled 
receptors, such as the GPER) and activation of protein kinase cascades or alterations in the 
levels of secondary messengers, resulting in (C) the activation of transcription factors that 
regulate gene expression or (D) rapid non-genomic effects, such as the activation of 
specific enzymes. While genomic actions can take hours to days, non-genomic effects 
occur in seconds or minutes. In addition, ERs can be activated and regulate gene 
expression in a ligand-independent manner (E) through phosphorylation (P) in response to 
growth factor binding to their membrane receptors. Natural estrogens may compete with 
several EDCs (represented by different colors and shapes) for multiple receptors and 
pathways, resulting in a complex response that depends on the cellular context in terms of 
receptors and interacting proteins and, thus, may differ between tissues and circumstances. 
cAMP, cyclic AMP; PKA, protein kinase A; PLC, phospholipase C; IP3, inositol  
1,4,5-triphosphate; DAG, diacylglycerol; PKC, protein kinase C. Adapted from [50]. 
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5. Mechanisms of Estrogenic Action in Mineralized Tissues 
The mechanism of action of E2 and other estrogenic compounds on the mammalian skeleton have 
been the focus of several recent reviews [22,23,58–60]. These appear to be complex and involve the 
interaction of E2 with other signaling pathways important for skeletal development and homeostasis 
that are activated by other hormones and factors, such as cytokines (e.g., interleukin-6, a major 
regulator of OSC formation and bone resorption), growth factors (e.g., insulin-like growth factor-I, 
IGF-I, regulator of bone linear growth) and parathyroid hormone (PTH) [23,58,61]. In addition, 
estrogenic effects on the skeleton include both direct actions on OSB, OSC, osteocytes and their 
precursor cells, as well as indirect effects, through regulating the crosstalk between cell types and released 
paracrine factors, which together orchestrate bone remodeling (for more detail, see [23,58,60]). 
At the cellular level, direct actions via intracellular ERs that are localized in OSB, OSC and 
osteocytes [23,25,58,62,63] may include classical effects on gene expression [64] and also involve 
interaction with other TFs [23,58,65,66], and a number of bone estrogenic effects are mediated by  
non-nuclear actions of ERs or related receptors [58,67–69]. In addition, ligand-independent actions of 
ERs in mammalian bone were also recently identified and appear to differ between bone types [70]. 
There are thus multiple pathways and targets where EDCs can potentially interfere in bone, and 
although from fish to mammals there is evidence for the disruption of bone physiology by EDCs (see 
Section 7), the mechanisms involved are yet to be detailed [71]. 
Table 1. Detection of estrogen receptor isoforms in fish mineralized tissues. 
Species Tissue 
Transcript/Protein 
and Detection Method 
ERα ERβa ERβb References 
Sparus auratus Endochondral bone (jaw) Transcript (qRT-PCR) √ (low) √ √ [72] 
Sparus auratus Dermal bone (skull) Transcript (RT-PCR) - √ √ [46] 
Sparus auratus 
Perichondral bone  
(vertebral centra) 
Transcript (qRT-PCR) √ (low) √ √ [72,73] 
Sparus auratus Chondroid bone (gill arches) Transcript (qRT-PCR) √ (low) √ √ 
[73] 
Sparus auratus Cartilage (Intervertebral disc) Transcript (RT-PCR) - √ √ 
[46] 
S. auratus;  
Oreochromis mossambicus; 
Carassius auratus; 
Oncorhynchus mykiss; 
Scales 
Transcript (RT-PCR); 
Protein (IHC) 
√ (low) √ √ [32,40,46] 
Sparus auratus Skin with scales Transcript (qRT-PCR) √ (low) √ √ [42] 
RT-PCR, reverse transcription polymerase chain reaction; qRT-PCR, quantitative RT-PCR; IHC, immunohistochemistry; 
low, low level of expression. 
In fish, the mechanisms responsible for the effects of estrogens in mineralized tissues are mostly 
unexplored. Transcripts for the three fish ER isoforms were detected in different fish mineralized 
tissues (Table 1), with a higher abundance of the ERβa and βb isoforms. In the scales of sea bream and 
Mozambique tilapia (Oreochromis mossambicus), the three ER protein isoforms were detected in putative 
OSC [46], suggesting that the E2-induced Ca mobilization and increase in scale OSC activity [34,37] 
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may result from direct actions in these cells. In contrast, fish ERs were not detected in scale OSB, 
despite the fact that E2 is able to alter fish scale OSB activity [37,40], raising questions about its 
mechanism of action. 
In sea bream, transcript levels for ERβa were upregulated by E2 in both intact skin-scale and in 
regenerating skin after scale removal, while ERβb was downregulated by E2 in regenerating skin [42]. 
In addition, the selective ER modulator (SERM), raloxifene (an ER agonist in mammalian bone),  
upregulated both ERβa and βb in dentary bone and downregulated ERβa in vertebra [72]. Taken 
together, these studies suggest that estrogenic compounds most probably exert at least part of their 
actions on the fish skeleton or skin-scale through the duplicate ERβs (especially the βa isoform),  
rather than ERα. 
In common with mammals, it appears that the expression, localization and regulation of different 
ER isoform in fish differ between different types of mineralized tissues [42,46,72] (Table 1), probably 
giving rise to different responsiveness to estrogens and to the potential for interaction or different 
actions between ER isoforms. The relative and tissue-specific role of ER isoforms in mediating 
estrogenic actions in fish mineralized tissues, as well as the expression and involvement of other 
possible players (e.g., ER variants, membrane ERs, other hormones or their receptors) will need 
further investigation. Recently, GPER transcripts were detected in sea bass (Dicentrarchus labrax) 
scales, indicating another possible mechanism of action for E2 and EDCs (author’s unpublished  
results, [74]). 
Finally, evidence exists that indicates that the E2 effects on fish scales may also be in part mediated 
by other hypercalcemic factors, such as members of the parathyroid hormone (PTH)/PTH-related 
protein (PTHrP) family [75], shown to regulate scale OSC/OSB activities in vitro and reduce scale Ca 
content in vivo [35,76]. In fact, cross-talk occurs between E2 and PTH/PTHrP, and in vivo injections of 
a PTH/PTHrP receptor antagonist also partly inhibit the E2 stimulated hypercalcemic effect [77].  
In vitro treatment of goldfish scales with E2 stimulates both OSB and OSC activities and upregulates 
mRNA expressions of IGF-I and cathepsin K, which are respectively OSB/OSC markers, and it will be 
interesting in the future to analyze the change in expression or activity of other paracrine factors in 
scales or different types of fish bone in response to E2 and other estrogenic compounds. 
6. Estrogenic Endocrine Disruption 
In the context of the diversity of mechanisms and receptors for estrogens, it is now clear that in a 
given cell context, the mode of action of a certain compound as an agonist, antagonist or a SERM 
(compounds with agonist or antagonist estrogenic actions depending on the tissue) depends not only 
on its structure, but also on tissue- and cell-specific factors (summarized in Table 2) [7,51]. In fish, the 
existence of an additional ER isoform relative to other vertebrates [45] adds another layer of 
complexity to the diversity of possible estrogenic ER-mediated mechanisms of action. 
The most studied EDCs are estrogenic [7], and as previously indicated, there is a wide range of 
structurally diverse compounds from both natural and anthropogenic sources that have estrogenic 
effects and to which humans and wildlife may be exposed, via the diet or from the surrounding 
environment (examples are given in Section 1 and Figure 1) [6,78]. The four main factors may explain 
the high susceptibility of the estrogen system to disruption by diverse EDCs, namely: 
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(1) The high number of natural and anthropogenic chemical compounds with structural similarity 
to natural estrogens [78]; 
(2) The high promiscuity of ERs and the ability of their binding pocket to accommodate and be 
activated or repressed by a wide range of (structurally diverse) lipophilic compounds [51,79]; 
(3) The different levels of the estrogen system components that can be disrupted, including the 
enzymatic pathways involved in steroid biosynthesis and/or metabolism (still poorly explored), 
as well as the target cell final actions [13,80]; 
(4) The diversity of receptors, mechanisms and signaling pathways involved in the cellular action 
of estrogens, which are also targets for EDCs (see Section 4 and Figure 2) [7,51]. 
Table 2. Factors that influence the cellular response to an estrogenic EDC. 
Factor Influence 
Structure of the chemical: 
Determines binding to a given receptor and the resulting receptor 
conformation (agonist or antagonist-type) 
Cellular 
context: 
Diversity and functional 
characteristics of 
receptors 
The expression, sub-cellular localization and functional 
characteristics of intracellular ERs, their variants or membrane 
ERs/GPERs determine the signaling pathways that are activated or 
repressed 
Diversity of coregulators 
The cellular context in terms of the presence and levels of  
co-repressors and/or co-activators greatly influences cell-specific 
effects on an estrogenic ligand 
Diversity of other 
transcription factors 
The diversity of other transcription factors influences the possibility 
of indirect actions on alternative genes 
The importance of mineralized tissues for animal health and survival across vertebrates (Section 2), 
makes understanding the estrogenic and/or antiestrogenic effects of EDCs on this tissue a priority 
(Section 3), particularly taking into consideration the vast range of putative estrogenic EDCs and the 
fact that estrogen responsiveness is tissue-specific. However, until now, the vast majority of studies of 
estrogenic EDCs in fish have screened exclusively for disruptive effects on reproduction. 
7. Estrogenic Endocrine Disruption in Mineralized Tissues 
In tetrapods, exposure to environmental contaminants, particularly EDCs, is known to affect both 
OSB and OSC functions and bone characteristics. Moreover, in mammals, exposure to EDCs during 
the perinatal period may have an impact during adult life, while other effects may be a consequence of 
exposure at any time during life, and different effects have been reported for different bone types 
(reviewed by [71]). Several in vivo and in vitro EDC exposure studies carried out in mammals, 
amphibians and reptiles support the hypothesis that the disruption of cellular actions involved in bone 
formation and remodeling may have consequences for bone architecture, strength, density (mineral 
content) and characteristics (hardness and elasticity) [71,81,82]. 
However, relatively few studies (summarized in Table 3) have evaluated the impact of estrogenic 
EDC exposure on mineralized tissue in fish. The impact of these compounds was analyzed using  
in vivo and in vitro approaches and mostly using as endpoints OSB and OSC activity, plasmatic Ca 
levels, the incidence of bone anomalies and the expression of molecular markers associated with bone 
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formation (receptor activator of the NF-κB ligand (RANKL) and IGF-I) and resorption (TRAP and 
cathepsin K). 
Results suggest that some EDCs can have an impact on skeletal development, morphology and 
anomalies in fish, including the environmental contaminants, 17 alpha-ethynylestradiol (EE2), 
bisphenol A (BPA), 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), PCB 77 and the estrogen antagonist, 
ZM189,154 (ZM) [83–86]. However, morphological abnormalities may be insensitive indicators,  
since long exposure and high concentrations are required to have an overt effect [83], and they may 
also not be related to endocrine disruption [87]. Nonetheless, the exposure of fish to polluted water 
from sewage treatment plants with putative estrogenic effects caused detectable changes in hemal 
spine morphology [88]. 
The effects of several EDCs were observed on scale TRAP and ALP enzymatic activities, used 
respectively as markers for OSC and OSB activities [34,40,89]. Bisphenol A and two monohydroxylated 
polycyclic aromatic hydrocarbons (OHPAHs) suppressed both osteoclast and osteoblast activity [37,90], 
while tributyltin acetate (TBTA) did not affect OSC activity [91]; and PCB 118 increased it [92]  
(Table 3). 
The mechanisms mediating these effects were not established, although the transcript abundance of 
OSB markers (IGF-I and RANKL) and OSC markers (TRAP and cathepsin K) was analyzed [37,90,92]. 
IGF-I transcript abundance was unaltered by exposure of goldfish scales to BPA, but was  
downregulated, together with cathepsin K, by 4-OHBaA, an OHPAH. In contrast, the exposure of 
goldfish scales to E2 upregulated both transcripts [37], and PCB 118 upregulated cathepsin K, TRAP 
and RANKL [92]. Several of these contaminants have previously been shown or predicted to bind 
and/or activate fish ERs (e.g., [87,93–95]), suggesting that part of the effect of these EDCs is via a 
direct action on intracellular ER expression in fish scales. 
The diverse methodology and limited endpoints measured, such as changes in enzyme activity, 
morphology or targeted gene transcripts, together with the diversity of EDC doses tested in different 
freshwater and marine fish species, makes it difficult to compare the outcomes of studies. A 
comparison of the impact of putative estrogenic EDCs contaminating aquatic environments, using a 
common methodology and a range of endpoints, would facilitate the understanding of their 
mechanisms of action on OSB and OSC and their precursor cells. In fact, recent recommendations 
from the scientific community and public organizations have highlighted the need to identify 
molecular markers for xenoestrogen actions on target tissues, so that they can be included in risk 
assessment, particularly of wildlife [13,16,78,96–98]. 
It is clear that, even if only the marine environment is considered, when screening EDCs for  
their impact on fish mineralized tissue and on E2-regulated processes, several factors need to be taken 
into consideration: 
(1) The diverse fish species of ecological and commercial interest, in the wild or reared in 
aquaculture units, which may have different responses; 
(2) The endpoints that should be evaluated to assess EDC effects and elucidate the mode of action; 
(3) The tissue-specific responses to EDCs. For example, scales are proposed to be a preferential 
site for E2-induced Ca mobilization compared to bone [33,39], and they are directly exposed to 
the aquatic environment and for these reasons have been preferentially studied as an EDC 
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target tissue (Table 1). However, the estrogenic EDCs impacts on the fish endoskeleton and 
different bone types (endochondral, dermal, chondroid) need to be studied, as they respond 
differently to estrogenic compounds [46,72]; 
(4) The number of contaminants present in the aquatic environment both alone (in different 
concentrations) or in complex mixtures that may have an estrogenic disrupting action. 
In addition, it is likely that the compounds that disrupt bone metabolism in mammals [71] may also 
have disruptive estrogenic actions in fish bone and/or scales, when the conservation of the estrogenic 
axis in mineralized tissue between fish and mammals is taken into consideration. Moreover, many 
EDCs already have identified disruptive actions on fish reproductive tissues and bind and/or transactivate 
fish ERs (e.g., [16,78,87,94,99–103]), and together, these may be good starting candidates to 
investigate the impact of EDCs in fish mineralized tissues. 
The study of EDC effects represents an endless, but necessary task to prevent future damage to fish 
species, wildlife and human welfare in general. More specifically, estrogenic disruption of mineralized 
tissues may have a wide range of consequences, since an increase in skeleton anomalies, modified 
bone density and mineral homeostasis may impact on swimming and capacity to capture prey and 
escape from predators. In addition, the protective role of scales and their contribution to mineral 
(mainly Ca/P) homeostasis may be compromised and affect wild and cultured fish fitness and 
productivity in aquaculture units. An indirect impact of EDC-induced modifications in mineralized 
tissue that has so far not been considered is the effect of modified Ca availability on reproductive 
success, and this may reinforce the impact of EDCs on the reproductive system. 
There are several EDC testing programs being implemented by non-governmental advisory bodies 
throughout the world in order to identify or predict the endocrine disruptive effects of compounds and 
to prioritize the screening of environmental EDCs [87,97,98,104]. Most of these tests include in vivo 
assays with fish, since this is a group with clearly documented adverse impacts of EDCs. Testing tends 
to use small fish species, easily reared and with a short life cycle and is mainly focused on 
reproductive endpoints, e.g., the fish short-term reproduction assay (which evaluates the effects of 
exposure on secondary sexual characteristics, vitellogenin levels, fecundity and gonad histopathology 
in adult fish) or the fish sexual development test (which evaluates the effects of exposure during 
development on vitellogenin levels and sex ratio) [11,16,97,105,106]. 
The acknowledged limitations of current tests are their failure to cover mechanisms of action,  
the need to sacrifice fish and their time-consuming and/or expensive character [16,87,96]. 
Recent trends are to implement alternative in vitro, short-term assays to detect estrogenic endocrine 
disruption. For the risk assessment of putative estrogenic EDCs, recommended tests include ER ligand 
binding, cell-free assays, yeast reporter gene assays, cell line reporter assays, primary cell culture, as 
well as embryo and organ culture tests for many fish species [87] However, the existing assays are 
uninformative about EDC effects on mineralized tissues, and data about the adverse effects on these 
tissues are still limited. Future studies to cover a wider range of estrogenic EDCs, doses and fish 
species are required and could benefit from the inclusion of rapid test methods for mineralized tissues. 
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Table 3. Selected examples of the reported effects of estrogenic disrupting compounds on fish mineralized tissues. 
Species Compound Effective Dose 
Exposure Type  
and Period 
Endpoint Effect Reference 
Pimephales promelas 
17α-ethynylestradiol 
(EE2) 
0.1 to 100 μg/L 
In vivo, from 24 hpf to 
25–26 dph 
Degree of skeletal 
development; spinal 
abnormalities 
Modified skeletal developmental; vertebral 
malformations in up to 62% of fish 
[86] 
Bisphenol A (BPA) 1000 μg/L 
No impairment of skeletal development or vertebral 
malformations; decreased developmental score 
Fundulus heteroclitus 
17α-ethynylestradiol 
(EE2) 1000 to 10,000 ng/L  
10 and 10,000 ng/L 
In vivo, first 25 or 60 day 
of life 
Skeletal and soft tissue 
abnormalities 
Increased % of abnormal fish; increased number of 
abnormalities per fish 
[83] 
ZM189,154(ZM) 
Increased incidence of scoliosis; decreased overall 
incidences of abnormal fish and lordosis 
Gambusia holbrooki 
Sewage (two sewage 
treatment plants) 
n.a. n.a. 
Hemal spines 
morphology 
Modified hemal spines with one sewage source 
[88] 
Carassius auratus Bisphenol A (BPA) 10−6 to 10−5 M In vitro, scale assay (6 h) 
TRAP and ALP activity; 
transcript expression 
Suppressed OSB and OSC activity; no changes in 
IGF-I expression [90] 
Carassius auratus 
(freshwater);  
Girella punctata and 
Pseudolabrus sieboldi 
(marine) 
Tributyltin acetate 
(TBTA) 
10−9 to 10−5 M In vitro, scale assay (6 h) TRAP and ALP activity 
Inhibits OSB activity;  
no effect on OSC activity [91] 
Carassius auratus 
(freshwater); 
Pseudolabrus sieboldi 
(marine) 
3- and 4-OHBaA 10−7 to 10−5 M 
In vitro, scale assay  
(6 and 18 h) 
TRAP and ALP activity;  
transcript expression 
Inhibited OSB and OSC activities  
4-OHBaA down-regulated cathepsin K and  
IGF-I expression 
[37] 
Carassius auratus 
Polychlorinated 
biphenyl (PCB 118) 
100 ng/g BW  
0.0025–2.5 ppm 
In vivo, intraperitoneal 
injection (2 days)  
In vitro, scale assay  
(6 and 18 h) 
TRAP and ALP activity 
in scales  
Ca level in plasma  
transcript expression 
Increased OSC activity; hypercalcemia; increased 
OSC and OBS activity; upregulated cathepsin K, 
TRAP and RANKL expression 
[92] 
Sparus auratus Raloxifene 3.33 mg/kg BW 
In vivo, intraperitoneal 
injection (6 days) 
Ca level in plasma 
balance; transcript 
expression in dermal and 
perichondral bone 
No change in Ca levels; downregulation of genes 
related to bone formation and resorption in vertebra 
(perichondral bone) 
[72] 
ALP, alkaline phosphatase; BW, body weight; dph, days post-hatch; hpf, hours post-fertilization; IGF-I, insulin-like growth factor I; OSB, osteoblasts; OSC, osteoclasts; RANKL, receptor activator of the NF-κB 
ligand; TRAP, tartrate-resistant acid phosphatase; 3-OHBaA, 3-hydroxybenz[a]anthracene; 4-OHBaA, 4-hydroxybenz[a]anthracene. 
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Non-invasive, less expensive and more rapid tests are essential, and the fish scale assay may 
represent an interesting option that can be used simultaneously for many different fish species, but it 
needs to be optimized, validated and established as a high throughput test. The use of recent 
technologies based on genomics, transcriptomics or proteomics will provide insight into the 
mechanisms of estrogens’ actions [14] and, if applied to fish mineralized tissues, could be used to 
identify possible biomarkers representing different endpoints of EDC exposure. 
8. Conclusions 
Estrogens regulate calcified tissue physiology and mineral homeostasis across vertebrate, and 
despite the general conservation of OSB and OSC functions, their regulation by estrogens appears to 
differ between mammals and fish, presumably as a consequence of specific adaptations of their bone 
structure and metabolism. 
Fish mineralized tissues express intracellular ERs, although their expression and regulation appears 
to depend on the tissue, and preliminary results suggest that fish scales also express plasma membrane 
estrogen receptors. Further studies are required to localize receptors in different fish bone tissues and 
cell types and to detail their regulation by estrogens throughout the reproductive season and in 
response to environmental factors or other hormones. The expression of ERs in fish mineralized tissues 
indicates that they may be targets for the direct effects of E2 and the potential disruption by EDCs 
present in the environment or in the diet, and candidate compounds for testing this include those with 
an effect on mammalian bone or on fish reproductive tissues. Until now, relatively few studies have 
demonstrated the effects of EDCs on fish mineralized tissues, and studies of endocrine disruption on 
the teleost scale (which mainly used as endpoint OSC/OSB activities, Ca levels or morphology) are 
limited in the number of endpoints, species, compounds, doses and possible mechanisms investigated. 
In addition, the diversity of fish species (over 30,000) and the species-specific response of fish bone to 
E2 mean generalizations about the impact of EDCs are of limited usefulness. 
Further investigation of the action of EDCs on fish mineralized tissue is required and should 
include, amongst other things: 
(1) Screening of a far greater number of EDCs, including endpoints, such as the assessment of 
enzyme activities, gene expression, proteome changes and gene networks and cellular pathways; 
(2) Characterization of tissue-specific responses (e.g., bone type and bone versus scale); 
(3) Establishment of species-specific, season-specific and age-specific responses; 
(4) Determination of the impact of estrogenic disruption on fish health and survival. 
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